|
|
| Maladies Infectieuses > Etude de marché sectorielle |
|
|
|
|
€ 3 091,00 |
Editeur
: |
Global Industry Analyst |
Langue
: |
Anglais |
Date de publication : |
Octobre 2005 |
Taille du document : |
481 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Recommendations for Diagnostic Testing for Hepatitis B
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Stakeholder Opinions: Sexually Transmitted Infections - The Silent Menace
118 pages | Novembre 2005 |
IntroductionThe global incidence of STIs is estimated at several hundreds of millions cases per year, and due to the asymptomatic nature of most infections, underreporting is likely to mask the real i |
3 230,00 €
|
| |
| |
Antiviral HIV Treatment in Developing Countries Number of Patients
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Recommendations for Diagnostic Testing for Hepatitis C
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Pipeline Insight: HIV - Hold Your Horses
216 pages | Avril 2005 |
IntroductionIn the current antiretroviral landscape, resistance in all three of the established classes is proving to be problematic.
Accordingly, current clinical trials are recruiting treatment-r |
9 120,00 €
|
| |
| |
Hepatitis C Statistics
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Pipeline Insight: HIV - Hold Your Horses
216 pages | Avril 2005 |
IntroductionIn the current antiretroviral landscape, resistance in all three of the established classes is proving to be problematic.
Accordingly, current clinical trials are recruiting treatment-r |
9 120,00 €
|
| |
| |
Stakeholder Insight: HIV - A way of life
284 pages | Octobre 2005 |
IntroductionHIV is now considered a chronic, manageable disease.
However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are be |
12 920,00 €
|
| |
| |
Stakeholder Insight: Hepatitis in China - Liver Let Die?
310 pages | Décembre 2005 |
IntroductionHepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally.
HBV vaccination, together with HBV and |
12 920,00 €
|
| |
| |
Gen-Probe Clinical Diagnostic Products for the Detection of Viral Microorganisms
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
This report analyzes the worldwide markets for Human Vaccines in Millions of US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East, and Latin America. Annual forecasts are provided for each region for the period of 2001 through 2010. A ten-year historic analysis is also provided for these markets with annual market analytics. The report profiles 73 companies including many key and niche players worldwide such as ALK – Abelló, Acambis,Sanofi-Aventis, Sanofi-Pasteur SA, Sanofi Pasteur Inc., Bavarian Nordic, Berna Biotech AG, GreenCross Vaccine, Rhein Biotech NV, Chiron Corporation, PowderJect Pharmaceuticals PLC, CSL Ltd., GlaxoSmithKline, Medimmune, Inc., Merck & Company, Inc., Shanta Biotechnics, Vaxin, Inc., and Wyeth.
|
|
|
PPLSEN
|
|
|
|
|
